Peter Trill active positions
| Companies | Position | Start | End |
|---|---|---|---|
Duke Street Bio Ltd.
 Duke Street Bio Ltd. BiotechnologyHealth Technology Duke Street Bio Ltd. is a British precision medicine company that targets specific genetic alterations in cancer using a DDR vulnerability approach. The company is based in London, UK. The company's goal is to deliver life-saving cancer treatments to improve patient outcomes. The company was founded in 2020. The CEO is Alan Wisee. | Chairman | - | - |
| Director/Board Member | - | - |
Career history of Peter Trill
Former positions of Peter Trill
| Companies | Position | Start | End |
|---|---|---|---|
IOmet Pharma Ltd.
 IOmet Pharma Ltd. Drugstore ChainsRetail Trade IOmet Pharma Ltd. develops drugs and related products. It focuses on developing the novel ideas sourced from universities, research institutes and industry as well as internally generated programs. The company was founded by Peter Trill and Tom Brown in 2010 and is headquartered in Scotland, the United Kingdom. | Director of Finance/CFO | 2010-05-19 | - |
| Founder | 2010-05-19 | - |
Statistics
International
| United Kingdom | 3 |
Operational
| Director of Finance/CFO | 1 |
| Founder | 1 |
| Director/Board Member | 1 |
Sectoral
| Retail Trade | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
IOmet Pharma Ltd.
IOmet Pharma Ltd. Drugstore ChainsRetail Trade IOmet Pharma Ltd. develops drugs and related products. It focuses on developing the novel ideas sourced from universities, research institutes and industry as well as internally generated programs. The company was founded by Peter Trill and Tom Brown in 2010 and is headquartered in Scotland, the United Kingdom. | Retail Trade |
Duke Street Bio Ltd.
Duke Street Bio Ltd. BiotechnologyHealth Technology Duke Street Bio Ltd. is a British precision medicine company that targets specific genetic alterations in cancer using a DDR vulnerability approach. The company is based in London, UK. The company's goal is to deliver life-saving cancer treatments to improve patient outcomes. The company was founded in 2020. The CEO is Alan Wisee. | Health Technology |
- Stock Market
- Insiders
- Peter Trill
- Experience
